share_log

基石藥業-B:自願公告 - 基石藥業宣佈舒格利單抗治療復發或難治性結外NK/T細胞淋巴瘤的新適應症在中國獲批,成為首個獲批此適應症的PD-1或PD-L1單克隆抗體

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES NMPA APPROVAL OF SUGEMALIMAB FOR PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, THE FIRST ANTI-PD-1/PD-L1 MAB APPROVED FOR THIS INDICATION

香港交易所 ·  Oct 30, 2023 20:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more